Compare Novartis AG (NVS) vs iShares Semiconductor ETF (SOXX) Price & Performance

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

SOXX, the iShares Semiconductor ETF, trades at $528.40, up 1.64% on the day, reflecting strong momentum driven by AI infrastructure demand. The technical outlook is bullish, with moving averages supporting an uptrend and key resistance at $533. Recent news highlights surging power demand in South Korea linked to chipmaker expansions and AI data centers, underscoring sector growth catalysts. A 1:3 stock split is scheduled for November 2026, potentially enhancing accessibility.

The ETF's outlook remains positive, fueled by robust AI-driven semiconductor demand and institutional inflows, though risks include potential tariff hikes and market volatility. Analysts are broadly optimistic, citing diversified exposure to top performers like Nvidia and AMD. Investors should weigh near-term overcrowding risks against long-term structural growth in AI and memory markets.